Close
FINDING CURES TOGETHER<sup>SM</sup>

Melanoma: From Biology to Target

​Program

Tuesday, Jan. 15 

Friday, Jan. 18


Thursday, Jan. 15

Welcome and Keynote Session
4-5 p.m.

In vivo crosstalk between melanoma cells and the human immune system
Meenard Herlyn, The Wistar Institute, Philadelphia, Pennsylvania


Opening Reception
5-6:30 p.m.


Wednesday, Jan. 16

Continental Breakfast
7-8 a.m.


Plenary Session 1: Understanding Resistance to Checkpoint Blockade
8-10 a.m.

Targeting the TIGIT/CD226 axis in melanoma
Hasane M. Zarour, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania


Response and resistance to checkpoint blockade therapy
Antoni Ribas, University of California, Los Angeles, California

Overcoming immune resistance with rationally designed combination immunotherapy
Roberta Zappasodi, Memorial Sloan Kettering Cancer Center, New York, New York

2 short talks from proffered abstracts


Break
10-10:30 a.m.


Plenary Session 2: Unique Biology of Melanoma
10:30 a.m.-12:30 p.m.

Distinct immune and molecular features of melanoma brain metastases            
Michael A. Davies, The University of Texas MD Anderson Cancer Center, Houston, Texas

Angiotropism, pericytic mimicry and extravascular migratory metastasis in melanoma: A historical perspective
Claire Lugassy, Institut Curie, Paris, France 

Understanding the role of tumor-resident dendritic cells for anti-tumor immunity
Stefani Spranger, MIT Koch Institute for Integrated Cancer Research, Cambridge, Massachusetts

2 short talks from proffered abstracts


Free Time (Lunch on Own)
12:30-2:30 p.m.


Plenary Session 3: Melanoma Metabolism
2:30-4:30 p.m.

Elevated endogenous SDHA drives pathological metabolism in highly metastatic uveal melanoma
Chandrani Chattopadhyay, The University of Texas MD Anderson Cancer Center, Houston, Texas

Title to be announced
Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, PA

Title to be announced
Paul B. Chapman, Memorial Sloan Kettering Cancer Center, New York, New York

2 short talks from proffered abstracts


Poster Session A / Reception
4:45-7:15 p.m.


Thursday, Jan. 17

Continental Breakfast
7-8 a.m.


Plenary Session 4: Early Melanoma Detection and Prevention
8-10 a.m.

Oregon’s war on melanoma: Harnessing the power of early detection
Sancy A. Leachman, Oregon Health & Science University, Portland, Oregon

Preventing melanoma progression through a genomic approach
Marianne Berwick, University of New Mexico Health Sciences Center-Albuquerque, Albuquerque, New Mexico

Opportunities and challenges in melanoma early detection
David Polsky, New York University School of Medicine, New York, New York

2 short talks from proffered abstracts


Break
10-10:30 a.m.


Plenary Session 5: Non-Cutaneous Melanoma and Rare Cutaneous Subtypes
10:30 a.m.-12:30 p.m.

Unique biology and treatment implications in uveal melanoma
Richard D. Carvajal, Columbia University Medical Center, New York, New York

Novel genomic and transcriptomic aberrations in acral compared to sun-exposed melanomas
Ruth Halaban, Yale University, New Haven, Connecticut

The landscape of mucosal melanoma: A long way to go
Jun Guo, Peking University Cancer Hospital & Institute, Beijing, China 

2 short talks from proffered abstracts


Poster Session B / Lunch
12:30-3 p.m.


Plenary Session 6: Targeting Driver Pathways Beyond BRAF
3-5 p.m.

Defining the actionable genome
David B. Solit, Memorial Sloan Kettering Cancer Center, New York, New York

Therapeutic opportunities gleaned from melanoma's unique pathogenesis
David E. Fisher, Massachusetts General Hospital, Boston, Massachusetts

Role of autophagy in cancer
Eileen P. White, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Identifying new immune targets in malignant melanoma
Marcus W. Bosenberg, Yale University, New Haven, Connecticut


Break
5-5:15 p.m.


Special Session: Proffered Talks from Highly Rated Abstracts
5:15-6:45 p.m.


Friday, Jan. 18

Continental Breakfast
7-8 a.m.


Plenary Session 7: Intersection of the Tumor and Immune Microenvironment
8-10 a.m.

Translating immunotherapy from melanoma to other skin cancers
Suzanne L. Topalian, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Intrinsic tumor genomic and metabolic factors leading to immunoresistance
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Myeloid cell melanoma interface
Karolina Palucka, The Jackson Laboratory, Farmington, Connecticut

2 short talks from proffered abstracts


Break
10-10:30 a.m.


Plenary Session 8: BRAF and MEK Resistance
10:30 a.m.-12:30 p.m.

Are there non-immune targets in the BRAFV600 melanoma patient?
Jeffrey A. Sosman, Northwestern University, Chicago, Illinois

Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers
Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

Strategies to overcome MAPK inhibitor resistance
Roger S. Lo, University of California, Los Angeles, California

2 short talks from proffered abstracts


Closing Remarks
12:30-12:45 p.m.


Top of page